Schult, Catrin <br/><br/>
The dual kinase inhibitor NVP-BEZ235 in combination with cytotoxic drugs exerts anti-proliferative activity towards acute lymphoblastic leukemia cells.  [electronic resource] 

 -  Anticancer research  Feb 2012 
 - 463-74 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1791-7530 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Cell Cycle Checkpoints--drug effects<br/>Cell Growth Processes--drug effects<br/>Cell Line, Tumor<br/>Cytarabine--administration & dosage<br/>Dexamethasone--administration & dosage<br/>Doxorubicin--administration & dosage<br/>Drug Resistance, Neoplasm<br/>Drug Synergism<br/>Humans<br/>Imidazoles--administration & dosage<br/>Jurkat Cells<br/>Leukemia, B-Cell--drug therapy<br/>Oncogene Protein v-akt--antagonists & inhibitors<br/>Phosphatidylinositol 3-Kinase--metabolism<br/>Phosphoinositide-3 Kinase Inhibitors<br/>Precursor Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma--drug therapy<br/>Quinolines--administration & dosage<br/>Signal Transduction<br/>TOR Serine-Threonine Kinases--antagonists & inhibitors